Jagsonpal Pharmaceuticals Ltd Stock Price Today (NSE: JAGSNPHARM)
Fundamental Score
Jagsonpal Pharmaceuticals Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Jagsonpal Pharmaceuticals Ltd share price today is ₹172.98, up +0.00% on NSE/BSE as of 19 February 2026. Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.45K (Cr). The 52-week high for JAGSNPHARM share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 33.23x, JAGSNPHARM is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 18.58% and a debt-to-equity ratio of 0.03.
Jagsonpal Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Jagsonpal Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Jagsonpal Pharmaceuticals Share Price: A Financial Risk Analysis
One unique aspect of the pharmaceutical industry is its reliance on research and development, creating a constant need for innovation to maintain market share. This analysis examines the financial stability of Jagsonpal Pharmaceuticals Ltd., focusing on key metrics to assess its risk profile. Currently, the Jagsonpal Pharmaceuticals share price stands at ₹168.16. We will evaluate this price in light of the company’s performance and benchmark it against its sector peers.
The company's Price-to-Earnings (PE) ratio is 33.23. This is a valuation multiple, indicating what the market is willing to pay for each rupee of Jagsonpal's earnings. A higher PE ratio suggests either higher growth expectations or potential overvaluation. Comparatively, examining the management quality and strategic decisions of
Mankind Pharma Ltd offers a valuable perspective on how Jagsonpal's leadership stacks up within the industry. Evaluating these qualitative factors alongside quantitative data is critical for a comprehensive risk assessment.A crucial indicator of Jagsonpal Pharmaceuticals' efficiency is its Return on Capital Employed (ROCE) of 22.95%. This metric reflects how effectively the company generates profits from its invested capital. The high ROCE significantly contributes to the company’s economic moat. A wider moat, derived from sustained profitability, makes it more difficult for competitors to erode Jagsonpal's market position and pricing power.
Benchmarking against peers like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd, in terms of profitability margins, debt levels, and growth rates, would provide a more comprehensive perspective. This analysis is part of a broader 80-parameter fundamental audit of Jagsonpal Pharmaceuticals Ltd, verified by Sweta Mishra, to ensure a robust and rigorous assessment of the company's financial health. This evaluation presents an observation of the company's financial standing based on available data and should not be interpreted as investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Jagsonpal Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of JAGSNPHARM across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (18.58%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (22.95%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Excellent EPS Growth (37.78% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (38.15% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.03)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (54.51x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹207.42 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (67.54%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Limited Institutional Interest (FII+DII: 2.20%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Jagsonpal Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for Jagsonpal Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About JAGSNPHARM (Jagsonpal Pharmaceuticals Ltd)
Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹1.45K (Cr). Jagsonpal Pharmaceuticals Ltd has delivered a Return on Equity (ROE) of 18.58% and a ROCE of 22.95%. The debt-to-equity ratio stands at 0.03, reflecting the company's capital structure. Investors tracking JAGSNPHARM share price can monitor key metrics including P/E ratio, promoter holding of 67.54%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
JAGSNPHARM Share Price: Frequently Asked Questions
What is the current share price of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)?
As of 19 Feb 2026, 10:12 am IST, Jagsonpal Pharmaceuticals Ltd share price is ₹172.98. The JAGSNPHARM stock has a market capitalisation of ₹1.45K (Cr) on NSE/BSE.
Is JAGSNPHARM share price Overvalued or Undervalued?
JAGSNPHARM share price is currently trading at a P/E ratio of 33.23x, compared to the industry average of 31.77x. Based on this relative valuation, the Jagsonpal Pharmaceuticals Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of JAGSNPHARM share price?
The 52-week high of JAGSNPHARM share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Jagsonpal Pharmaceuticals Ltd share price?
Key factors influencing JAGSNPHARM share price include quarterly earnings growth (Sales Growth: -0.29%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Jagsonpal Pharmaceuticals Ltd a good stock for long-term investment?
Jagsonpal Pharmaceuticals Ltd shows a 5-year Profit Growth of 38.15% and an ROE of 18.58%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.03 before investing in JAGSNPHARM shares.
How does Jagsonpal Pharmaceuticals Ltd compare with its industry peers?
Jagsonpal Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare JAGSNPHARM share price P/E of 33.23x and ROE of 18.58% against the industry averages to determine competitive standing.
What is the P/E ratio of JAGSNPHARM and what does it mean?
JAGSNPHARM share price has a P/E ratio of 33.23x compared to the industry average of 31.77x. Investors pay ₹33 for every ₹1 of annual earnings.
How is JAGSNPHARM performing according to Bull Run's analysis?
JAGSNPHARM has a Bull Run fundamental score of 59.9/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does JAGSNPHARM belong to?
JAGSNPHARM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Jagsonpal Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for JAGSNPHARM?
JAGSNPHARM has an ROE of 18.58%, which indicates excellent management efficiency. ROE measures how efficiently Jagsonpal Pharmaceuticals Ltd generates profits from shareholders capital.
How is JAGSNPHARM debt-to-equity ratio and what does it indicate?
JAGSNPHARM has a debt-to-equity ratio of 0.03, which indicates conservative financing with low financial risk.
What is JAGSNPHARM dividend yield and is it a good dividend stock?
JAGSNPHARM offers a dividend yield of 1.15%, meaning you receive ₹1.15 annual dividend for every ₹100 invested in Jagsonpal Pharmaceuticals Ltd shares.
How has JAGSNPHARM share price grown over the past 5 years?
JAGSNPHARM has achieved 5-year growth rates of: Sales Growth 11.13%, Profit Growth 38.15%, and EPS Growth 37.78%.
What is the promoter holding in JAGSNPHARM and why does it matter?
Promoters hold 67.54% of JAGSNPHARM shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Jagsonpal Pharmaceuticals Ltd.
What is JAGSNPHARM market capitalisation category?
JAGSNPHARM has a market capitalisation of ₹1454 crores, placing it in the Small-cap category.
How volatile is JAGSNPHARM stock?
JAGSNPHARM has a beta of N/A. A beta > 1 suggests the Jagsonpal Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is JAGSNPHARM operating profit margin trend?
JAGSNPHARM has a 5-year average Operating Profit Margin (OPM) of 13.66%, indicating the company's operational efficiency.
How is JAGSNPHARM quarterly performance?
Recent quarterly performance shows Jagsonpal Pharmaceuticals Ltd YoY Sales Growth of -0.29% and YoY Profit Growth of 9.69%.
What is the institutional holding pattern in JAGSNPHARM?
JAGSNPHARM has FII holding of 2.12% and DII holding of 0.08%. Significant institutional holding often suggests professional confidence in the Jagsonpal Pharmaceuticals Ltd stock.